ADAstrid Irene Díez-Martín

Astrid Irene Díez-Martín

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Astrid Irene Díez-Martín has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Joaquín Cubiella

    Grupo de Investigación en Oncología Digestiva-Ourense (GIODO), Fundación Biomédica Galicia Sur, 32003 Ourense, Spain

    14 shared publications
  • Pedro Davila-Piñón

    Grupo de Investigación en Oncología Digestiva-Ourense (GIODO), Fundación Biomédica Galicia Sur, 32003 Ourense, Spain

    9 shared publications
  • Cristina Regueiro

    Grupo de Investigación en Oncología Digestiva-Ourense (GIODO), Fundación Biomédica Galicia Sur, 32003 Ourense, Spain

    7 shared publications
  • David Remedios

    Department of Gastroenterology, Hospital Universitario de Ourense, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 32005 Ourense, Spain

    7 shared publications
  • Sara Zarraquiños

    Department of Gastroenterology, Hospital Universitario de Ourense, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 32005 Ourense, Spain

    7 shared publications
  • Alba Nogueira-Rodríguez

    Department of Computer Science, ESEI - Escuela Superior de Ingeniería Informática, Universidade de Vigo, Ourense 32004, Spain; Next Generation Computer Systems Research Group (SING), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Spain

    5 shared publications

Latest Publications

  • Open Access

    Diagnostic Accuracy and Colonoscopy-Sparing Potential of RAID-CRC Screen After a Positive Faecal Immunochemical Test

    by Cristina Regueiro-Expósito, Anais Crespo, Astrid Díez-Martín, Pedro Davila-Piñón, Joaquín Cubiella

    Background/Objectives: Faecal immunochemical test (FIT)-based colorectal cancer (CRC) screening generates many colonoscopy referrals without advanced neoplasia. We evaluated RAID-CRC Screen, a qPCR-based faecal bacterial signature, as second-line triage after positive FIT in the Galician population-based screening programme. Methods: This cross-sectional diagnostic accuracy study included participants with FIT ≥ 100 ng haemoglobin/mL and colonoscopy as reference standard. RAID-CRC Screen was analysed from residual FIT-buffer material. The primary analysis included evaluable assays and complete colonoscopy. An additional intention-to-diagnose analysis assigned non-evaluable results to colonoscopy referral. Comparisons with data-derived alternative FIT thresholds were exploratory. Results: Among 1291 participants in the primary analysis, 34 (2.6%) had CRC and 441 (34.2%) advanced neoplasia. RAID-CRC Screen was positive in 1087 (84.2%). Sensitivity was 94.1% (95% CI, 80.3–99.3%) for CRC and 87.5% (84.1–90.5%) for advanced neoplasia; specificities were 16.1% (95% CI, 14.1–18.2%) and 17.5% (95% CI, 15.0–20.3%), respectively. RAID-CRC Screen after FIT100 would avoid 204 colonoscopies (15.8%; 95% CI, 13.9–17.9%) while missing two CRCs and 55 advanced neoplasms. FIT118 alone would avoid 149 colonoscopies (11.5%), with CRC sensitivity of 100.0% (95% CI, 89.7–100.0%) and advanced neoplasia sensitivity of 92.3% (95% CI, 89.4–94.6%). In the intention-to-diagnose analysis (1312), including 21 non-evaluable results, colonoscopy reduction was 15.5% (95% CI, 13.6–17.6%), with the same two CRCs not referred. Conclusions: RAID-CRC Screen triage reduced modelled colonoscopy referrals at the cost of missed CRCs and advanced neoplasia. FIT118 alone avoided fewer colonoscopies while retaining all observed CRCs. These exploratory comparisons do not establish superiority or the safety of withholding colonoscopy.

  • Open Access

    Beyond Taxonomy: Fungal Nutraceutical Supplementation Modifies the Functional Potential of the Gut Microbiome in Colorectal Cancer

    by Nahir Rodríguez-Costas, Arturo Rodríguez-Blanco, Cristina Regueiro Expósito, Joaquín Cubiella, Esteban Sinde Stompel, Catalina Fernández-De-Ana Portela, Astrid Irene Diez Martín, Pablo Taboada-Rodríguez, Belén Fontán Silva, María Dolores Rodríguez Fernández, et al.

    The gut microbiome is increasingly recognized as an important determinant of host immune regulation, intestinal homeostasis, and recovery after colorectal cancer (CRC) surgery. Although our previous randomized, double-blind, placebo-controlled clinical trial demonstrated that fungal nutraceutical supplementation with Micodigest® was associated with favorable taxonomic and systemic inflammatory changes in patients undergoing CRC surgery with curative intent, the functional consequences of this intervention remain poorly understood. Here, we performed a functional metagenomic analysis of fecal samples collected from patients enrolled in the original clinical trial to investigate whether Micodigest® supplementation was associated with changes in the functional potential of the gut microbiome. A total of 37 patients were analyzed, including 24 receiving Micodigest® and 13 receiving placebo, with paired samples collected before supplementation and after 4–6 weeks of intervention. Shallow shotgun metagenomic sequencing was performed, and microbial functional potential was characterized using KEGG Orthologues (KOs). Differential abundance analysis identified 14 significantly different KOs between groups at baseline and 23 after intervention, with no overlap between the two sets of orthologues. Following supplementation, Micodigest®-treated patients exhibited increased representation of functions related to CRISPR-associated systems, bacteriophage biology, and chitin-derived carbohydrate utilization, together with reduced representation of nutrient acquisition systems, conjugative transfer, sulfur metabolism, and components of the Wood–Ljungdahl pathway. These functional signatures suggest coordinated changes in microbial ecological adaptation, nutrient utilization, genetic exchange, and metabolic activity following fungal nutraceutical supplementation. Integration with previously reported taxonomic and inflammatory findings supports the hypothesis that Micodigest® may promote coordinated remodeling of the gut microbiome and host–microbiota interactions during the perioperative period. Although the present study cannot establish causality or directly infer microbial activity from metagenomic potential, these findings provide novel functional insights into the microbiome response to fungal nutraceutical supplementation in patients with CRC and highlight functional metagenomics as a valuable complement to taxonomic profiling.

  • Open Access

    Diagnostic Accuracy and Colonoscopy-Sparing Potential of RAID-CRC Screen after a Positive Faecal Immunochemical Test

    by Cristina Regueiro-Expósito, Anais Crespo, Astrid Díez-Martín, Pedro Dávila-Piñón, Joaquín Cubiella

    Background/Objectives: Faecal immunochemical test (FIT)-based colorectal cancer (CRC) screening generates many colonoscopy referrals without advanced neoplasia. We evaluated RAID-CRC Screen, a qPCR-based faecal bacterial signature, as second-line triage after positive FIT in the Galician population-based screening programme. Methods: This prospective diagnostic accuracy study included participants aged 50–69 years with FIT ≥100 ng haemoglobin/mL buffer and colonoscopy as reference standard. RAID-CRC Screen was analysed from residual FIT-buffer material. Alternative FIT thresholds were compared with RAID-CRC Screen triage. Results: Among 1296 participants, 33 (2.5%) had CRC and 444 (34.3%) advanced neoplasia. RAID-CRC Screen was positive in 1161 (89.6%). Sensitivity was 97.0% (95% CI, 84.2–99.9%) for CRC and 91.2% (88.2–93.7%) for advanced neoplasia; specificities were 10.6% and 11.3%, respectively. RAID-CRC Screen after FIT100 would avoid 135 colonoscopies (10.4%), while missing one CRC and 39 advanced neoplasms. FIT118 alone would avoid 147 colonoscopies (11.3%), detect all 33 CRCs, and provide 92.3% sensitivity for advanced neoplasia. Conclusions: RAID-CRC Screen preserved high CRC sensitivity but, at FIT100, did not provide a more favourable observed trade-off than modestly increasing the FIT threshold.

  • Open Access

    Organised Colorectal Cancer Screening and Changes in Mortality and Incidence Trends: A Population-Based Study

    by Astrid Díez-Martín, Margarita Castro, Isolina Santiago, Raquel Almazán, Ángel Gómez-Amorín, Cristina Regueiro-Expósito, Pedro Davila-Piñón, Joaquín Cubiella

    Background: Organised colorectal cancer (CRC) screening programmes have been widely implemented across Europe; however, robust population-level evaluations of their real-world effectiveness, particularly for programmes based exclusively on faecal immunochemical testing (FIT), remain limited. The Galician CRC screening programme was progressively implemented between 2013 and 2019. Methods: We conducted a population-based ecological time-series study using data from the Galician Tumour Registry (ICD-10 C18–C21) for 2015–2023. Age-standardised mortality (ASMR) and incidence (ASIR) rates were analysed. They were calculated using the direct standardisation method, applying age-specific rates to the 2013 European Standard Population (ESP2013). Structural changes associated with programme implementation were evaluated using interrupted time-series (ITS) models, estimating annual percent change (APC) before and after implementation and the net change in slope (ΔAPC). Absolute and relative changes in ASMR and ASIR were calculated by comparing 2015–2017 and 2019–2023. Analyses were performed for the overall population and for individuals aged 50–69 years. Results: Between 2015 and 2023, overall CRC mortality declined significantly (APC −3.00%; 95% CI −3.37 to −2.63). ITS analysis demonstrated a marked modification of mortality trajectories following programme implementation. Mortality shifted from an increasing pre-implementation slope (APC +13.70%; 95% CI 10.12, 17.39) to a significant annual decline post-implementation (APC −3.62%; 95% CI −4.47, −2.76), yielding a ΔAPC of −17.32. In individuals aged 50–69 years, the structural change was more pronounced (ΔAPC −19.88), with post-implementation mortality decreasing by −8.08% annually (95% CI −10.43, −5.66). Incidence showed a comparable structural modification. Overall APC changed from +15.26% (95% CI 5.48, 25.95) before implementation to −2.48% (95% CI −5.29, 0.41) afterwards (ΔAPC −17.74). In the screening-eligible population, APC shifted from +21.32% (95% CI 4.60, 40.71) to −3.74% (95% CI −7.62, 0.30), corresponding to a ΔAPC of −25.06. Descriptively, ASMR declined from 41.92 to 35.91 per 100,000 (−14.33%), and ASIR from 98.37 to 85.16 per 100,000 (−13.42%) between 2015 and 2017 and between 2019 and 2023. Relative reductions were larger in individuals aged 50–69 years and were more pronounced for colon cancer than for rectal cancer. Conclusions: Implementation of an organised FIT-based screening programme was associated with a structural change in CRC mortality and incidence trends, particularly among individuals aged 50–69 years.


  • Open Access

    Organized Colorectal Cancer Screening and Changes in Mortality and Incidence Trends: A Population-Based Study

    by Astrid Díez-Martín, Margarita Castro, Isolina Santiago, Raquel Almazán, Ángel Gómez-Amorín, Cristina Regueiro-Expósito, Pedro Davila-Piñón, Joaquín Cubiella

    Background: Organized colorectal cancer (CRC) screening programs have been widely implemented across Europe; however, robust population-level evaluations of their real-world effectiveness, particularly for programmes based exclusively on faecal immunochemical testing (FIT), remain limited. The Galician CRC screening programme was progressively implemented between 2013 and 2019. Methods: We conducted a population-based ecological time-series study using data from the Galician Tumour Registry (ICD-10 C18–C21) for 2015–2023. Age-standardized mortality (ASMR) and incidence (ASIR) rates were analyzed. Structural changes associated with program implementation were evaluated using interrupted time-series (ITS) models, estimating annual percent change (APC) before and after implementation and the net change in slope (ΔAPC). Absolute and relative changes in ASMR and ASIR were calculated by comparing 2015–2017 and 2019–2023. Analyses were performed for the overall population and for individuals aged 50–69 years. Results: Between 2015 and 2023, overall CRC mortality declined significantly (APC −3.00%; 95% CI −3.37 to −2.63). ITS analysis demonstrated a marked modification of mortality trajectories following program implementation. Mortality shifted from an increasing pre-implementation slope (APC +13.70%; 95% CI 10.12, 17.39) to a significant annual decline post-implementation (APC −3.62%; 95% CI −4.47, −2.76), yielding a ΔAPC of −17.32. In individuals aged 50–69 years, the structural change was more pronounced (ΔAPC −19.88), with post-implementation mortality decreasing by −8.08% annually (95% CI −10.43, −5.66). Incidence showed a comparable structural modification. Overall APC changed from +15.26% (95% CI 5.48, 25.95) before implementation to −2.48% (95% CI −5.29, 0.41) afterwards (ΔAPC −17.74). In the screening-eligible population, APC shifted from +21.32% (95% CI 4.60, 40.71) to −3.74% (95% CI −7.62, 0.30), corresponding to a ΔAPC of −25.06. Descriptively, ASMR declined from 41.92 to 35.91 per 100,000 (−14.33%), and ASIR from 98.37 to 85.16 per 100,000 (−13.42%) between 2015–2017 and 2019–2023. Relative reductions were larger in individuals aged 50–69 years and were more pronounced for colon cancer than for rectal cancer. Conclusions: Implementation of an organized FIT-based screening program was associated with a structural change in CRC mortality and incidence trends, particularly among individuals aged 50–69 years.


  • Open Access

    PIBAdb: a public cohort of multimodal colonoscopy videos and images including polyps with histological information

    by Alba Nogueira-Rodríguez, Rubén Domínguez-Carbajales, Fernando Campos-Tato, Jesús Herrero, Manuel Puga, Laura Rivas, Eloy Sánchez, Águeda Iglesias, Laura Codesido, Ástrid Irene Díez-Martín, et al.


  • Open Access

    Tackling Post‐Endoscopy Gastric Cancer in a Low‐Risk Area: Prevalence, Features, and Prevention Opportunities Through Better Clinical Practice

    by Ricard Prat, Joan Llach, Sheyla Montori, Anabella Cuestas, Nayra Felípez, Alba Valero, Pedro Delgado‐Guillena, Javier Tejedor‐Tejada, Elena Arruebo, Silvia Patricia Ortega, et al.

    Background: Post‐endoscopy gastric cancer (PEGC) is a gastric cancer (GC) diagnosed within 3 years after an esophago‐gastro‐duodenoscopy (EGD) negative for cancer. Post‐endoscopy gastric cancer has a prevalence of 9%–11% in the western population and is potentially reducible through adequate surveillance and high‐quality endoscopy. However, Post‐Endoscopy Gastric Cancer features are not well defined. Objectives: Define Post‐Endoscopy Gastric Cancer prevalence in a gastric cancer low‐risk area as Spain, describe its characteristics and associated factors. Evaluate adherence to current recommendations for surveillance of preneoplastic gastric lesions and endoscopic quality indicators. Methods: A descriptive and analytical study included patients who met PEGC criteria and enrolled in the EpiGASTRIC registry—a national multicentric GC cohort—between April 2021 and May 2024. Results: Of 289 gastric cancer patients analyzed, 21 (7.3%) presented with PEGC. No differences were found between PEGCs and new‐onset gastric cancers (NOGC) regarding clinical‐demographic characteristics (males 52.4%, 65 years, caucasians 78.9%, previous Helicobacter pylori infection 56.3%) except for use of proton pump inhibitors (PPI) (81.0% vs. 44.9%, p ‐value = 0.002). Distal stomach (antrum and/or incisure) was more frequently affected in PEGC compared with NOGC (71.4% vs. 46.2%; p ‐value = 0.022), without differences in tumoral staging (I–II 52.4%) or histology (intestinal type 47.6%). Median time from last negative‐for‐cancer EGD to diagnosis was 13.6 months (interquartile range 4.1–26.8), with 38.1% of precursor lesions in previous endoscopy (19% chronic atrophic gastritis with metaplasia, 19% dysplasia). Considering last negative‐for‐cancer EGD, adherence to current recommendations was 66.6% for the surveillance of gastric lesions, and 14.3% for quality indicators (complete procedure 100%, high‐definition 38.1%, chromoendoscopy 10.0%). Conclusions: PEGC patients present a higher rate of distal stomach involvement and use of PPIs. Although precursor gastric lesions are commonly identified, adherence to current recommendations for their surveillance and to established quality indicators in EGDs is scarce. Despite its low prevalence, there is room for improvement to enhance the early detection and prevention strategies for PEGC.


  • Open Access

    Clinical Evaluation of PolyDeep, A Computer-Aided Detection System: A Multicenter Randomized Tandem Colonoscopy Trial

    by Pedro Davila-Piñón, Astrid Irene Díez Martín, Alba Nogueira-Rodríguez, Ruben Domínguez-Carbajales, Florentino Fdez-Riverola, Sara Zarraquiños, Luisa de Castro, Jesús Herrero, Nereida Fernández, Pablo Vega, et al.

    Background/Objectives: Computer-aided detection (CADe) systems are increasingly used in endoscopy to enhance lesion recognition. PolyDeep is a CADe/x tool previously assessed in an observational study. The aim of our study is to determine if PolyDeep-assisted colonoscopy reduces the adenoma miss rate (AMR) compared with conventional colonoscopy. Methods: We carried out a multicenter randomized controlled trial with a tandem colonoscopy design in participants from a colorectal cancer screening program (positive fecal immunochemical test-FIT or surveillance). Expert endoscopists performed all colonoscopies, and patients were allocated to groups by a computer-generated sequence. The primary endpoint was AMR; secondary endpoints included polyp miss rate (PMR), serrated lesion miss rate (SLMR) and advanced polyp miss rate (APMR). Results: From May to November 2023, we recruited 260 patients and excluded 20, leaving 240 for analysis. Baseline characteristics were balanced between groups (62.1% male; mean age 62.3 ± 6.5 years; 65.8% FIT-positive; mean first withdrawal time 13:38 ± 08:07 min; mean second withdrawal time 07:50 ± 03:38 min; lesion detection rate 76.6%; mean polyps per patient 3.4 ± 3.1). We did not find statistically significant differences between PolyDeep-assisted and conventional colonoscopy groups in AMR (21.3% vs. 18.1%, p = 0.5), PMR (21.8% vs. 20.3%, p = 0.7), SLMR (23.4% vs. 25.6%, p = 0.9) or APMR (7.3% vs. 11.3%, p = 0.5). In the subgroup analysis according to indication, we did not find any statistically significant differences. Conclusions: In the context of a CRC screening program, PolyDeep-assisted colonoscopy did not reduce AMR.


  • Open Access

    Genomic diversity and BCL9L mutational status in circulating tumor cells predict overall survival in metastatic colorectal cancer

    by Joao M. Alves, Nuria Estévez-Gómez, Roberto Piñeiro, Laura Muinelo-Romay, Patricia Mondelo-Macía, Mercedes Salgado, Agueda Iglesias-Gómez, Laura Codesido-Prada, Astrid Diez-Martín, Joaquin Cubiella, et al.

    Background: Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related mortality, but few noninvasive biomarkers exist to track disease progression or inform treatment strategies. Circulating tumor cells (CTCs) offer a minimally invasive source of tumor material, yet the prognostic significance of their genomic diversity remains unclear. Methods: We conducted whole-exome sequencing of CTC pools from 29 mCRC patients to characterize their mutational landscape and assess associations with overall survival. Results: Our analysis revealed substantial variation in mutational burden among patients, with all CTC pools harboring non-silent mutations in key CRC driver genes. Higher genomic diversity in CTC pools was significantly associated with reduced overall survival. Additionally, non-silent mutations in BCL9L emerged as a strong predictor of patient survival. Conclusion: Genomic diversity and BCL9L mutational status in CTC pools emerged as strong predictors of survival in mCRC, underscoring the potential of CTC genomic profiling as a minimally invasive and clinically relevant prognostic tool in mCRC.


  • Open Access

    Clinical Evaluation of PolyDeep, a Computer Aided Detection system: A Multicenter Randomized Tandem Colonoscopy Trial

    by Pedro Davila-Piñón, Astrid Irene Díez Martín, Alba Nogueira-Rodríguez, Ruben Domínguez-Carbajales, Florentino Fdez-Riverola, Sara Zarraquiños, Luisa de Castro, Jesús Herrero, Nereida Fernández, Pablo Vega, et al.

    Background/Objectives: Computer-aided detection (CADe) systems are increasingly used in endoscopy to enhance lesion recognition. PolyDeep is a CADe/x tool previously assessed in an observational study. The aim of our study is to determine if PolyDeep-assisted colonoscopy reduces the adenoma miss rate (AMR) compared with conventional colonoscopy. Methods: We carried out a multicenter randomized controlled trial with a tandem colonoscopy design in participants from a colorectal cancer screening program (positive fecal immunochemical test-FIT or surveillance). Expert endoscopists performed all colonoscopies, and patients were allocated to groups by a computer-generated sequence. The primary endpoint was AMR; secondary endpoints included polyp miss rate (PMR), serrated lesion miss rate (SLMR) and advanced polyp miss rate (APMR). Results: From May to November 2023, we recruited 260 patients and excluded 20, leaving 240 for analysis. Baseline characteristics were balanced between groups (62.1% male; mean age 62.3 ± 6.5 years; 65.8% FIT-positive; mean first withdrawal time 13:38 ± 08:07 minutes; mean second withdrawal time 07:50 ± 03:38 minutes; lesion detection rate 76.6%; mean polyps per patient 3.4 ± 3.1). We did not find statistically significant differences between PolyDeep-assisted and conventional colonoscopy groups in AMR (21.3% vs 18.1%, p = 0.5), PMR (21.8% vs 20.3%, p = 0.7), SLMR (23.4% vs 25.6%, p = 0.9) or APMR (7.3% vs 11.3%, p = 0.5). In the subgroup analysis according to indication, we did not find any statistically significant differences. Conclusions: In the context of a CRC screening program, PolyDeep-assisted colonoscopy did not reduce AMR.